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The functional properties of glycoproteins are strongly influ-
enced by their profile of glycosylation, and changes in this profile
are seen inmalignancy. In mucin-typeO-linked glycosylation these
changes can result in the production of mucins such as MUC1,
carrying shorter sialylated O-glycans, and with different site
occupancy. Of the tumor-associated sialylatedO-glycans, the disac-
charide, sialyl-Tn (sialic acid 2,6GalNAc), is expressed by
30% of breast carcinomas and is the most tumor-specific. The
ST6GalNAc-I glycosyltransferase,which can catalyze the transfer of
sialic acid to GalNAc, shows a highly restricted pattern of expres-
sion in normal adult tissues, being largely limited to the gastroin-
testinal tract and absent in mammary gland. In breast carcinomas,
however, a complete correlation between the expression of RNA-
encoding ST6GalNAc-I and the expression of sialyl-Tn is evident,
demonstrating that the expression of sialyl-Tn results from switch-
ing on expression of hST6GalNAc-I. Endogenous or exogenous
expression of hST6GalNAc-I (but not ST6GalNAc-II) always results
in the expression of sialyl-Tn. This ability to override core 1/core 2
pathways of O-linked glycosylation is explained by the localization
of ST6GalNAc-I, which is found throughout the Golgi stacks. The
development of a Chinese hamster ovary (CHO) cell line expressing
MUC1 and ST6GalNAc-I allowed the large scale production of
MUC1 carrying 83% sialyl-Tn O-glycans. The presence of
ST6GalNAc-I in the CHO cells reduced the number ofO-glycosyla-
tion sites occupied in MUC1, from an average of 4.3 to 3.8 per tan-
dem repeat. The availability of large quantities of this MUC1 glyco-
form will allow the evaluation of its efficacy as an immunogen for
immunotherapy of MUC1/STn-expressing tumors.
Post-translational modifications of proteins can strongly affect
their function. In this context it is becoming clear that glycosylation
plays an important role in eukaryotes, not merely in the stabilization
of proteins in vivo, but in affecting cell-cell interactions and interac-
tions with the matrix, as well as affecting the function of intracellular
molecules such as transcription factors (1–3). In the development of
malignancy, interactions of the cancer cell with other cells and mat-
rices in different tissues are crucially important for survival and/or
metastasis and interactions with immune effector cells can affect the
immune response. In this context, cancer-associated changes in the
glycosylation patterns of glycoproteins that transit the Golgi path-
way and are either secreted or targeted to the membrane are of
particular interest. In many carcinomas that express membrane and
secreted mucins, changes in mucin-type O-glycosylation have been
documented (4). In the change to malignancy in the breast, changes
in the glycosylation of the MUC1 mucin has been extensively stud-
ied, following both the composition and density of the O-glycans
added (5–8), and the profile of glycosyltransferases expressed
(9–13). Because MUC1 is expressed by 90% of breast cancers, the
carcinoma-associated glycoforms are being considered as targets
both for exogenously administered antibodies (14) and for active
specific immunotherapy using MUC1-based immunogens (15, 16).
Mucin type O-glycosylation is initiated by the addition of
N-acetylgalactosamine (GalNAc) to serines and threonines, which
generates the Tn antigen, and in the normal breast chains are
extended by the addition of monosaccharides through the core
1/core 2 pathways. This results in the addition of linear and branched
polylactosamine side chains to the core protein of MUC1 (see Fig. 1
and Ref. 8). In breast cancers and breast cancer cell lines, there is a
shift toward the addition of shorter O-glycans, the degree to which
this change is seen being dependent, to some extent, on the level of
expression of the core 2 synthesizing enzyme, which can be totally
absent (6, 9). In addition, sialylation of the shorter O-glycans is
increased, thus terminating chain extension, and most breast can-
cers show an increase in the level of ST3Gal-I (10), which adds sialic
acid to core 1 to give Neu5Ac2,3Gal1,3GalNAc or SialylT (Fig. 1).
Although this O-glycan is found on many normal cells, including
resting lymphocytes, it is not normally found on MUC1 in breast,
and high expression is associated with aggressive disease and may be
immune suppressive (10, 17).
Sialylation of the first sugar, GalNAc, leading to the product
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Neu5Ac2,6GalNAc or Sialyl-Tn (STn)6 is a less common event, and
immunohistochemical analysis detected this O-glycan on 25–30% of
breast cancers (18, 19). Expression of STn in breast cancer correlates
with poor prognosis (20) and predicts a poor response to chemotherapy
(19), whereas expression of STn on normal tissues is highly restricted.
Thus the STnO-glycan has been seen as a possible target for therapeutic
intervention (21–24). In human cells, the enzyme ST6GalNAc-I has
been identified as a glycosyltransferase able to add sialic acid in 2,6
linkage to GalNAc linked to serine or threonine, thus creating the STn
epitope (25). Other sialyltransferases active in the pathway of mucin
type O-glycosylation, including hST6GalNAc-II, can add sialic acid in
2,6 linkage to GalNAc in vitro (26) but show a preference for GalNAc
residues already modified by the addition of galactose or galactose fol-
lowed by sialic acid in 2,3 linkage (26, 27).
Although STn has a highly restricted expression on normal tissues
(28–30), it is found on several types of carcinomas (19, 28, 31). The
mechanisms underlying the appearance of this O-glycan are not totally
clear and may vary with the tissue. One obvious mechanism is an
increase in the level of activity of the enzyme(s), which adds sialic acid to
GalNAc. Studies in colon carcinoma have demonstrated that this is not
the case in this malignancy (32), because the level of 2,6-sialyltransfer-
ase enzyme activity is similar in normal and cancerous colonic tissue,
whereas STn is only detectable in the cancers. The difference in colon
carcinoma appears to be due to a lack of detection of the STn on most
normal tissue, because of a modification of the sialic acid resulting in it
not being recognized by the STn-specific antibodies. However, as we
report here, although the hST6GalNAc-I mRNA, which synthesizes
STn, is found in normal tissues of the gastrointestinal tract, it is not
present in the normal breast. Therefore there is a strong possibility that
the expression of STn in breast cancer relates to the de novo expression
of hST6GalNAc-I.
Here we have examined this hypothesis and find a complete correla-
tion between the expression of the STn epitope in breast cancers and the
expression of hST6GalNAc-ImRNA. Significantly, there was no corre-
lation of STn expression with expression of hST6GalNAc-II mRNA.
Transfection studies show that expression of hST6GalNAc-I can over-
ride the core 1/core 2 pathway in breast cancer cell lines and that the
enzyme appears to be found throughout the Golgi. Thus stable expres-
sion of the enzyme has allowed the production of large quantities of a
MUC1 glycoform carrying STn as the dominant O-glycan.
MATERIALS ANDMETHODS
Cell Culture—The breast cancer cell line T47D was cultured in E4,
10% FCS, and the E2J cell line, derived from the transfection of T47D
with C2GnT-1 (13), was cultured in E4, 10% FCS with 500g/ml G418.
The myelogenous leukemia cell line, K562, was cultured in RPMI, 10%
FCS. CHO MUC1 cells were developed by transfection of CHO cells
with aMUC1-murine IgG2a fusion cDNA construct containing 16 tan-
dem repeats (36) and were initially cultured in Iscove’s modified Dul-
becco’s medium, 10% FCS with 600 g/ml G418. For large scale pro-
duction, they were adapted to serum-free medium (see below).
Cloning of hST6GalNAc-I by RT-PCR—Total cellular RNA was pre-
pared form K562 cells using TRIzol (Invitrogen) as per the manufactur-
er’s instructions. First strand cDNA synthesis was performed with oli-
go(dT) primers from 3 g of RNA in a 20-l reaction volume using a
superscript pre-amplification system (Invitrogen). The amplification of
cDNA was performed with the Expand Long template PCR system
(Roche Applied Science) in a total volume of 50 l containing 0.3 M of
a primer set, 5-GCTAGCCGACCCACCACCATGAGG-3
(corresponding to bp (12 to 6) of the ST6GalNAcI sequence) and
5-CTCGAGTCAATTACCAAGACGATTCATTTCAATATCAGT-
ATAAAGTTGACGATTGGGCGGGTTCTTGGCTTTGGCAGTT-
C-3 (corresponding to bp 1761–1800 of the ST6GalNAc-I sequence).
The 5-end of the published cDNA sequence (accession number Y
11339 (25)) was found to disagree with the genomic ST6GalNAc-I (ac-
cession number AC005837). The sequence of the 5-primer was taken
from the genomic sequence, because use of the published 5 cDNA
sequence did not result in a product. The primers were designed to
generate NheI and XhoI sites at the 5- and 3-ends, respectively.
The 3-oligonucleotide also generates a mutated stop codon in the
ST6GalNAc-I sequence followed by 2 proline residues, the vsv-g tag
sequence, and a TGA stop codon. PCR buffer 1 was used at a final
MgCl2 concentration of 1.75 mM. After initial denaturation for 3 min
at 94 °C, 30 cycles of PCR were performed, each cycle comprising
30 s at 94 °C, 30 s at 60 °C, and 2 min at 68 °C. The PCR product was
cloned into pCR2.1 using the Original TA cloning kit (Invitrogen),
sequenced and subcloned into pcDNA3.1-hygro (Invitrogen) using
NheI/XhoI restriction sites.
Cell Transfections—Cells were transiently transfected with 2 g of
ST6GalNAc-I-vsv or ST6GalNAc-II-FLAG expression plasmids using
10 l of the Lipofectamine reagent (Invitrogen) according to the man-
ufacturer’s instructions. T47D-ST3 (12) and CHO MUC1 cells were
stably transfected with 30 g of ST6GalNAc-I-vsv-g pcDNA3.1hygro
vector by electroporation using the following conditions: T47D-ST3,
250 V at 960 microfarads and CHO MUC1 450 V at 250 microfarads.
Three days post-transfection, cells were split 1:10 into E4, 10% FCSwith
500g/ml G418 and 300g/ml hygromycin (T47D-ST3-STn) and 1:20
into Iscove’s modified Dulbecco’s medium, 10% FCS with 600 g/ml
hygromycin, and 600 g/ml G418 (CHO MUC1 STn). Media was
changed every 3 days until selection of clones was isolated and
expanded.
6 The abbreviations used are: STn, Sialyl-Tn; T, Thomas-Friedreich antigen; ST6GalNAc,
CMP-Neu5Ac:GalNAc-R2,6-sialyltransferase; ST3Gal-I, CMP-NeuAc:Gal1,3GalNAc-
R2,3-sialyltransferase; C2GnT1, UDP-N-acetyl-D-glucosamine-Gal/GalNAc1,6-
N-acetylglucosaminyltransferase; core 1 enzyme, core 1 1,3-galactosyltransferase;
PNA, peanut agglutinin; vsv-g, vesicular stomatitis-g protein; KLH, keyhole limpet
hemocyanin; CHO, Chinese hamster ovary cells; FITC, fluorescein isothiocyanate; LC-
ESI, liquid chromatography-electrospray ionization; MS, mass spectrometry; FCS,
fetal calf serum.
FIGURE 1. Pathways of O-glycosylation in normal breast tissue and carcinoma.
O-Glycan structures on the normal epithelial cells of the breast are mainly core 2-based
resulting from the action of C2GnT1 on core 1 O-glycans. In breast carcinoma shorter
O-glycans are added, and sialylation of GalNAc and/or core 1 by ST6GalNAc-I or ST3Gal-I,
respectively, results in chain termination. Although some breast cancers and breast
cancer cell lines lose the C2GnT1 enzyme, others continue to express this
glycosyltransferase.
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Immunofluorescence Staining of Cultured Cells—Cells on coverslips,
fixed with 4% paraformaldehyde for 10 min at room temperature and
permeabilized by 0.1% Triton-X for 5 min at room temperature, were
washed and then incubated with the mouse monoclonal antibody
TKH2 (reactivewith STn) orwith the anti-vsv-g antibody (P5D4) for 1 h
at room temperature. Following three washes in phosphate-buffered
saline, rabbit anti-mouse FITC (Dako) was added for 1 h at room tem-
perature at a dilution of 1:40. For the detection of FLAG-tagged
ST6GalNAc-II expression, cells were incubated with a FITC-labeled
FLAG-M2 antibody (Sigma) for 1 h at room temperature. The cells were
washed, mounted in CITIFLUOR and viewed on a fluorescence
microscope.
Flow Cytometric Analysis—Cells were stained with monoclonal anti-
body SM3 (MUC1) orTKH2, 30min on ice, washed, and incubatedwith
FITC-conjugated rabbit anti-mouse immunoglobulins (Dako) for 30
min on ice. When biotinylated antibodies were used, binding was
detected with streptavidin-FITC (Dako). For internal staining of the
vsv-g tag, cells were incubated on ice with the anti-vsv-g antibody
(P5D4) in 0.1% saponin for 30 min followed by FITC-conjugated rabbit
anti-mouse immunoglobulins (Dako) for 30 min on ice. Cells were
stained with peanut agglutinin before and after sialidase treatment as
previously described (17). Cells were fixed in 1% formaldehyde and ana-
lyzed using an XL Flow Cytometer (Beckman-Coulter, HighWycombe,
UK) and WinMDA software. Dead cells were excluded on the basis of
forward and side light scatter.
Immunoelectron Microscopy—Cells were fixed for 1 h at room tem-
perature in 0.1% gluteraldehyde/4% paraformaldehyde before being
scraped, spun down, and stored overnight in 2% paraformaldehyde at
4 °C. The grids were incubated overnight at 4 °C with 20 g/ml P5D4
(reactive with the vsv-g tag), followed, after washing, with rabbit anti-
mouse IgG1 for 30 min. After further washing, grids were incubated at
room temperature for 30 min with protein A coupled to 10-nm gold
particles. The grids were embedded in 1.8% methyl cellulose/0.4% ura-
nyl acetate before examination using a Jeol 1010 transmission electron
microscope with a Gatan 2K digital camera for image capture.
RT-PCR of Glycosyltransferases—The generation of cDNA was per-
formed as described above for K562 cells. The cDNA was amplified
using 2.5 units of Taq polymerase in a total volume of 50l. The follow-
ing oligonucleotides were used for each glycosyltransferase: Core 1,
1,3-galactosyltransferase-specific primers; 5-ACAGAAATACACT-
TTCGGGAAATG-3 and 5-TCAAGGATTTCCTAACTTCACTT-
TT-3. These primers generate the full-length cDNA resulting in the
amplification of a 1112-bp fragment. The C2GnT-1-specific primers
used were 5-ATGCTGAGGACGTTGCTG-3 and 5-TCAGTGTT-
TTAATGTCTCCAA-3. These primers generate the full-length C2G-
nT-1 cDNA, amplifying a 1286-bp fragment. ST6GalNAcI oligonucleo-
tides used were 5-AAAGGAGTGACCACAGCAG-3 and 5-TCAG-
TTCTTGGCTTTGGCAGTTC-3. These primers generate a 1155-bp
fragment, which represents the message for the active full-length form
of ST6GalNAc-I. The MUC1-specific oligonucleotides used were
5-CTTGCCAGCCATAGCACCAAG-3 and 5-CTCCACGTCGTG-
GACATTGATG-3. These primers result in the amplification of a
region between the end of exon 2 and the beginning of exon 4 andwould
result in the generation of a 341-bp fragment from RNA and a 590-bp
fragment fromgenomic cDNA. PCR sampleswere run on an agarose gel
containing 1 g/ml ethidium bromide, and the gel was viewed under a
long wave UV transilluminator.
Northern Blotting—Total RNA of primary breast carcinoma tissue
was generated using TRIzol reagent (Invitrogen) according to the man-
ufacturer’s instructions followingmechanical disaggregation of samples
using a dismembranator on dry ice. Northern blots were preformed as
previously described (13). ST6GalNAc-I mRNA was detected using a
full-length probe, and ST6GalNAc-IImRNA was detected using a 1-kb
HindIII-XbaI fragment. ST6GalNAc-I mRNA expression in normal
human tissues was analyzed on amultiple tissue expression array (Clon-
tech, Basingstoke, UK) containing normal human tissue poly(A)
RNA, using the above full-length ST6GalNAc-I probe.
Western Blotting—CHO MUC1 STn cell culture supernatants were
collected for analysis of the secreted MUC1 protein. 20 l of superna-
tant was separated on a 10% SDS-polyacrylamide gel and then blotted
onto nitrocellulose membrane overnight. The blot was blocked over-
night at 4 °C in phosphate-buffered saline, 0.2% Tween 20, 1% bovine
serum albumin (PTB). For detection of the STn-carrying glycoprotein,
the blot was incubated at room temperature for 1 h with biotinylated
TKH2 (4 g/ml) in PTB. Following three washes in PTB the blot was
incubated at room temperature for 1 h with streptavidin-horseradish
peroxidase (1/1500 dilution in PTB). For the detection of total MUC1-
IgG in the supernatants, the blot was incubated directly with rabbit
anti-mouse serum (1/1500 dilution in PTB). After three additional
washes the bound antibody-streptavidin horseradish peroxidase com-
plex was detected using enhanced chemiluminescence (ECL) and light-
sensitive film.
Large Scale Production of MUC1-IgG-STn—CHO MUC1-
ST6GalNAc-I cells were grown in suspension in the serum-free
medium ProCHO4-CDM (BioWhittaker Europe). Continuous perfu-
sion fermentations with cell retention by spin filtration were done in a
standard stirred vessel bioreactor with a working volume of 1L (Appli-
con Biotek, Knuellwald, Germany) under controlled conditions as
described elsewhere (37). Cells were removed from supernatant by fil-
tration through a Sartobran 300 capsule with a 0.2-m cut-off (Sarto-
rius, Gottingen, Germany), and the cell-free supernatant was concen-
trated by ultrafiltration and rebuffered in 200 mM Tris/HCl buffer, pH
7.2, using an Ultrasette tangential flow device (Pall, Dreieich, Germany)
with a 100-kDa cut-off. The whole downstream processing was done at
a temperature of 0–4 °C.
O-Glycan Structure and Site Occupancy Determination by Liquid
Chromatography-Electrospray Ionization Mass Spectrometry—O-gly-
cans from 20 g of purified MUC1-IgG were released by reductive
-elimination and analyzed by LC-ESIMS (36). The relative amounts of
the different oligosaccharides were obtained from the integrated peak
areas in the chromatogram corresponding to each of themolecular ions
(Neu5Ac2–6)GalNAcol (m/z 513), Neu5Ac2–3Gal1–3GalNAcol
and Gal1–3(Neu5Ac2–6)GalNAcol (m/z 675), and Neu5Ac2–
3Gal1–3(Neu5Ac2–6)GalNAcol (m/z 966 and 483). The occupancy
of theO-glycosylation sites in MUC1 was determined as described pre-
viously (36), except that the treatment with Vibrio cholerae neuramin-
idase was performed at pH 4.5.–5.0 and the glycopeptides generated by
Clostripain digestion were analyzed by nano-LC-ESI MS using a
Finnegan LTQ mass spectrometer (Thermo Electron, Waltham, MA).
Integration of peaks in mass chromatograms was performed using
XCalibur software.
RESULTS
Expression of the STn O-Glycan Correlates with Expression of
hST6GalNAc-I butNot with hST6GalNAc-II in Primary Breast Cancer—Un-
like the situation with cells of the normal gastrointestinal tract, mRNA
coding for the hST6GalNAc-I enzyme is not expressed in the normal
human mammary gland (Fig. 2, G9).
To examine the correlation between STn expression and the expres-
sion of hST6GalNAc-I, we analyzed a series of 29 primary breast cancers
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for expression of hST6GalNAc-I mRNA and of STn. Immunohisto-
chemical analysis of the breast cancers was previously performed using
themonoclonal antibody TKH2, which recognizes single as well as clus-
tered STnO-glycans (38).Of the 29 breast carcinomas analyzed, 10were
found to express STn (Table 1). Six were highly positive while four cases
showed weaker staining. Using Northern blot analysis and a full-length
probe (Fig. 3a), it appeared that some of the tumors expressing STn did
not express detectable hST6GalNAc-I message. These were tumors
showing aweaker expression of STn (seeTable 1), but by using RT-PCR,
expression of the hST6GalNAc-I mRNA was detected (Fig. 3b, upper
panel).
Two isoforms of the hST6GalNAc-I mRNA have been described, a
functional full-length form and a shorter form, which has 250 bp of
sequence deleted and codes for an inactive protein (25). As the North-
ern analysis was performed with a full-length hST6GalNAc-I probe,
which would not discriminate between the two transcripts, primers for
RT-PCR analysis of hST6GalNAc-I were designed to detect the long
form of the message (see “Materials and Methods”). This gave rise to a
1.15-kb PCR product that represents the message coding for the active
form of hST6GalNAc-I (see Fig. 3b, upper panel). All of the STn-posi-
tive tumors were found to express the full-length transcript, whereas
none of the tumors that showed negative staining with the TKH2
expressed hST6GalNAc mRNA (Cases 28 and 29 were not analyzed
because tumor samples were no longer available). The combined data
from both the Northern and RT-PCR analysis demonstrate a complete
correlation between hST6GalNAc-I expression and expression of STn
in primary breast cancer (Table 1).
In breast, the normal pathway forO-glycan synthesis follows the core
1/core 2 route (see Fig. 1), with shorter core 1-based O-glycans being
more dominant in many breast cancers (6, 11). RT-PCR analysis of
STn-positive and -negative breast cancers showed that cDNAs coding
for the core 1-synthesizing enzyme (Fig. 3b, second panel) and the core
2-synthesizing enzyme C2GnT1 (Fig. 3b, third panel) were present at
various levels. This implies that hST6GalNAc-I, when present, can
competewith core 1 for theGalNAc substrate, at least to some extent, to
synthesize the STn O-glycan.
Although both the mouse and human ST6GalNAc-II have been
shown to synthesize STn in vitro (26, 39), a secreted form of human
ST6GalNAc-II apparently did not synthesize this disaccharide (27). To
analyze the expression of the human ST6GalNAc-II enzyme in breast
cancer 8 cases were selected from the 29 analyzed for expression of STn,
representing tumors with high, low, or no expression of this O-glycan.
(see Table 1). As illustrated in Fig. 4a, Northern blot analysis showed
TABLE 1








26   
23   
27   
4   
1   
28   NAa
29   NA
22   
10   
24   
13, 3, 20, 2, 12, 14   
21, 18, 7, 5, 19, 9, 8   
15, 16, 6, 11, 17, 25   
a NA, tissue not available.
FIGURE 2. ST6GalNAc-I mRNA shows a restricted pattern of expression in human
tissues. A dot blot of human tissues was analyzed using a full-length hST6GalNAc-I
probe. Tissues expressing high and moderate levels of hST6GalNAc-I are listed. Normal
mammary gland (G9) is negative for ST6GalNAc-ImRNA.
FIGURE 3. ST6GalNAc-ImRNA correlates with STn expression in primary breast can-
cers. a, Northern blot analysis of 29 breast carcinomas using a full-length ST6GalNAc-I
probe. K562wasusedas apositive control. STn status is recordedasor for each case,
determinedby immunohistochemical stainingwith antibodies to STn.b, RT-PCRanalysis
of STn-positive breast carcinomas detecting the functional form of ST6GalNAc-I (upper
panel), core 11,3-GalT (secondpanel), andC2GnT1 (third panel)wasperformed.Cases 13
and 16 are STn-negative andwere used as negative controls as they hadpreviously been
shown not to express ST6GalNAc-I by RT-PCR .
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that hST6GalNAc-IImRNAwas expressed in all of the 8 breast cancers
regardless of their STn status. Furthermore, four STn-negative breast
cancer cell lines were found to express hST6GalNAc-IImRNA (see also
Ref. 27), whereas K562 cells, which express STn and hST6GalNAc-I
(Fig. 3a), did not express hST6GalNAc-II (Fig. 4a). Interestingly, the
non-malignant breast epithelial cell line, MTSV1–7, did not express
ST6GalNAc-II. These results suggest that hST6GalNAc-II does not
play a role in STn synthesis in breast cancer.
Transfection of hST6GalNAc-I into Breast Epithelial Cell Lines
Results in the Expression of the STn O-Glycan—Most breast cancer cell
lines, including T47D, do not express the STn O-glycan or
hST6GalNAc-I mRNA (data not shown). To directly demonstrate that
hST6GalNAc-I can override existing pathways of O-glycosylation in
breast cancer cells (and direct the synthesis of STn), cDNA coding for
the human functional enzyme was cloned by RT-PCR from K562 cells
and transiently transfected into the human breast cancer cell line T47D.
T47D cells express core 1-based but not core 2 O-glycans (6), and the
transfected hST6GalNAc-I was able to compete with the core 1 enzyme
as demonstrated by the expression of STn seen by staining with the
anti-STn monoclonal antibody, TKH2 (Fig. 4b, panel E). As predicted,
the STn O-glycan was not synthesized in T47D cells transfected with
cDNA coding for the hST6GalNAc-II enzyme (Fig. 4b, panel J), con-
firming the key role of hST6GalNAc-I in the expression of STn in breast
cancer cells. Significantly, expression of both ST6GalNAc-I and
FIGURE 5. Immunoelectron microscopy of
T47D-ST3 cells permanently transfected with
hST6GalNAc-I-vsv-g cDNA. Sections prepared as
described under “Materials and Methods” were
stainedwith the P5D4 antibody followed by a rab-
bit anti-mouse antibody and then protein A cou-
pled to 10-nm gold particles. All photographs
show the distribution of the vsv-g-tagged
hST6GalNAc-I throughout the Golgi. a and b rep-
resent the same Golgi at different magnifications
(c and d show different Golgi apparatus). Bar,
0.2 m.
FIGURE 4. ST6GalNAc-II does not correlate with
STn expression in breast cancer and does not
direct synthesis of STn in transfected cells. a,
Northern blots using a 1-kb ST6GalNAc-II cDNA
probe for RNA extracted from primary breast can-
cers (upper panel), and breast cell lines (lower
panel). K562 was used as a control for a cell line
expressing the STn O-glycan. b, T47D cells were
transiently transfected with either myc-tagged
hST6GalNAc-I cDNA (upper panels A–E) or FLAG-
tagged hST6GalNAc-II cDNA (lower panels F–J).
48 h later, cellswere fixed and stainedwith an anti-
myc antibody (panels A and C for ST6GalNAc-I
transfectants), an anti FLAGantibody (panels F and
H for ST6GalNAc-II transfectants), or the TKH2 anti-
body recognizing the STn O-glycan (panels E and
J). Panels B, D, G, and I show the phase contrast
corresponding to panels C, E,H, and J, respectively.
Magnifications: A and F, 400; B, C, G, and H,
1260; and D, E, I, and J,630.
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ST6GalNAc-II could be detected using antibodies to the tags in a num-
ber of cells (Fig. 4b, panels A and F, respectively). Higher magnification
shows that both enzymes were expressed in a Golgi localization (Fig. 4b,
panels B, C, G, and H).
T47D cells have previously been transfected with the core 2 enzyme,
C2GnT-1 to develop the E2J cell line (13). This resulted in the expres-
sion of core 2O-glycans onMUC1 as demonstrated by the loss of reac-
tivity with the SM3 monoclonal antibody, which is blocked by core 2
structures (13, 17). Transfection of ST6GalNAc-I into E2J cells showed
that expression of this sialyltransferase also resulted in the expression of
STn in breast epithelial cells expressing core 2-based O-glycans (data
not shown).
ST6GalNAc-I Transferase Is Found throughout the Golgi Stacks in
Transfected Cells—The position of the core 1 enzyme in the Golgi path-
way has not been mapped, but the C2GnT1 (core 2 enzyme) is found
mainly in the cis Golgi (13). To be able to override the core 1/core 2
pathway, the hST6GalNAc-I enzymewould therefore be expected to be
either in the cisGolgi or throughout the Golgi stacks, as has been found
for some polypeptide GalNAc transferases (41). The vsv-g-tagged
hST6GalNAc-I construct was transfected into T47D-ST3 (previously
used to map the ST3Gal-I enzyme (12)) and a stable cell line selected
(T47D-ST3-STn), which expresses both STn and hST6GalNAc-I (data
not shown). Immunoelectronmicroscopywas used to position the loca-
tion of the enzyme within the Golgi. Sections of the transfected cells
were labeled with the monoclonal antibody (P5D4) to the vsv-g tag and
binding detected with rabbit anti-mouse antiserum, followed by 10-nm
gold-labeled protein A (see “Materials andMethods”). The Golgi stacks
in breast cancer cell lines such as T47D are not all as structurally well
organized as in normal cells. However, where they could be seen to be
linearly stacked, the enzyme appeared to be distributed throughout the
stacks, and some examples are shown in Fig. 5. Fig. 5a demonstrates that
there was no background labeling, because all the labeling is confined to
the Golgi and none is present in the nucleus. Themicrographs in Fig. 5
(b–d) show in more detail the distribution of the hST6GalNAc-I
enzyme, which is found throughout the Golgi of T47D cells.
FIGURE 6. Expression of glycosyltransferases,O-glycans, andMUC1 in K562 cells. a,
RT-PCR was performed on mRNA from K562 cells using the primers for MUC1 and the
C2GnT1, core 1, and ST6GalNAc-1 glycosyltransferases, as described under “Materials
and Methods.” b, FACS analysis of K562 cells. Top panel: expression of STn. Cells were
incubated with TKH2 (thick line) followed by FITC-conjugated rabbit anti-mouse immu-
noglobulins or with secondary antibody alone (thin line). Middle panel: expression of
MUC1. K562 cells were incubated with SM3 (thick line) followed by FITC-conjugated
rabbit anti-mouse immunoglobulins or secondary antibody alone (thin line). Bottom
panel: expressionofCore1 structures. Cellswere incubatedwithFITC-conjugatedpeanut
agglutininbefore (thin continuous line) or after (thick line) treatmentwithneuraminidase;
cells alone (thin dotted line).
FIGURE 7. Analysis of CHO cells expressing a MUC1 fusion protein carrying STn. a,
schematic representation of the MUC1-IgG2a fusion protein, EK, enterokinase cleavage
site. b, Western blot of secreted proteins from supernatants of CHO MUC1 cells (lane 1)
and theCHOMUC1ST6GalNAc-I transfectant (lane 2) cells. Blotswere probedwith rabbit
anti-mouse horseradish peroxidase (left) or biotinylated TKH2 followed by Streptavidin-
horseradish peroxidase (right). c, CHO MUC1-STn cells express the ST6GalNAc-I-vsv-g
fusion protein. CHOMUC1 cells (left) or CHOMUC1 ST6GalNAc-I cells (right) were perme-
abilized and stained with biotinylated anti vsv-g antibody P5D4 followed by FITC-la-
beled streptavidin (thick line) or FITC-labeled streptavidin alone (thin line).
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Endogenous Expression of hST6GalNAc-I in K562 Cells Is Associated
with Expression of the STn O-Glycan—The above data show that in
breast cancer cells hST6GalNAc-I can compete with existing glycosy-
lation pathways when expressed from the strong cytomegalovirus pro-
moter. The results from the analysis of primary breast cancers suggest
that hST6GalNAc-I can also access the GalNAc substrate when expres-
sion is driven by its own promoter. To confirm this, we analyzed the
human leukemia cell line K562, which expresses the STnO-glycan (Fig.
6b, top panel). RT-PCRwas used to demonstrate thatmRNA transcripts
coding for the hST6GalNAc-I, core 1 and core 2 enzymes were all pres-
ent (Fig. 6a), although ST6GalNAc-II is not (see Fig. 4). The expression
of MUC1 was also observed at the level of mRNA (Fig. 6a) and at the
protein level as demonstrated by reactivity with the SM3 monoclonal
antibody (Fig. 6b,middle panel). The presence of core 1 structures was
demonstrated by binding of peanut agglutinin lectin but only after treat-
ment with neuraminidase, indicating that the core 1 structures are pre-
dominantly sialylated (Fig. 6b, bottom panel). The level of core 2 struc-
tures was not directly analyzed. However, MUC1 reacted with SM3, the
binding of which is blocked by core 2 structures. This suggests that the
dominant O-glycans synthesized by K562 cells are sialylated core 1
structures and sialylated Tn and that the levels of endogenous
hST6GalNAc-I are sufficient to result in the expression of STn. It is
theoretically possible, that an as yet unidentified sialyltransferase is
responsible for STn synthesis in K562 cells. Transfectants with consti-
tutively reduced ST6GalNAc-ImRNA (developed using by RNA inter-
ference) could be developed to eliminate this possibility.
Stable Expression of hST6GalNAc-I in CHOCellsModifies theO-Gly-
cans of a Secreted MUC1 Glycoprotein—The STn O-glycan is relatively
tumor-specific, and clinical studies using STn coupled to KLH as an
immunogen have suggested that there may be clinical benefit for breast
cancer patients (23). It is possible that STn might be a more effective
immunogen if carried on a natural substrate such as the MUC1 mucin,
expressed in most breast cancers. A qualitative assessment of MUC1-
expressing T47D cells transfected with hST6GalNAc-I, indicated that
along with the STn O-glycans, some sialylated core 1 structures were
also present (data not shown). A quantitative analysis, however, requires
more material and this is often not possible to acquire with a mem-
brane-associated glycoprotein. Instead we turned to the production of a
secreted MUC1 protein in CHO cells. The construct that was trans-
fected into the CHO cells contains most of the extracellular domain of
MUC1, including 16 tandem repeats, fused to mouse IgG2a Fc to aid
secretion (36, 37) (Fig. 7a). This secreted glycoprotein (MUC1-IgG2a)
carries over 80% mono-sialylated core 1 structures (Neu5Ac2–
3Gal1–3GalNAc or ST) but no STn O-glycans. To produce a MUC1
glycoprotein carrying STn O-glycans (MUC1-IgG2a-STn), CHO cells
expressing the MUC1-IgG2a fusion protein were transfected with the
vsv-g-tagged hST6GalNAc-I cDNA.
Supernatants from selected clones were subjected to Western blot
analysis to detect total secreted MUC1 glycoprotein and MUC1-carry-
ing STn (Fig. 7b). A secretedMUC1 product was observed at170 kDa,
similar but slightly lower in molecular mass to the product produced by
TABLE 2
Comparison ofO-glycans andO-glycosylation site occupancy onMUC1-IgG produced in wild-type CHO cells (CHOMUC1) and in CHOMUC1
cells transfected with hST6GalNAc-I (CHOMUC1 ST6GalNAc-I)
CHOMUC1 ST6GalNAc-I CHOMUC1 (36)






Number of glycosylated sites (n) in the MUC1
tandem repeat
% Peptides with n sitesb





Sites per tandem repeat 3.8 4.3
a Mean of two separate sample preparations and analyses. Integrated peak areas in mass chromatograms for each oligosaccharide were used to calculate the relative amounts of
each structure. Areas were corrected for the different signal intensities obtained by neutral, mono-sialylated, and di-sialylated structures as previously described (50).
b Mean of three (CHOMUC1ST6GalNAc-I) or two (CHOMUC1) separate sample preparations and analyses. Peaks inmass chromatograms representingMUC1 tandem repeat
glycopeptides with n GalNAcs were integrated and expressed as a percentage of the area for all MUC1 tandem repeat glycopeptides.
FIGURE 8. Combined nano-LC-ESI mass spectra of MUC1 glycopeptides obtained
after neuraminidase and-galactosidase treatment and Clostripain digestion of a
secreted MUC1 from CHO cells transfected with hST6GalNAc-I. Peaks correspond to
MUC1 tandem repeat peptides with two to five GalNAcs. Inserted for comparison is the
corresponding spectrum for wt CHOMUC1.
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the parental CHOMUC1 cell line (Fig. 7b, left panel, lanes 1 and 2). This
indicated that the hST6GalNAc-I-transfected cells secrete aMUC1 gly-
coprotein carrying shorterO-glycans. The presence of STnwas demon-
strated by probing the blot with a biotinylated TKH2 antibody followed
by horseradish peroxidase-conjugated streptavidin (Fig. 7b, right panel,
lane 2). Expression of hST6GalNAc-I was demonstrated by intracellular
FACScan analysis using a biotinylated anti vsv-g antibody (Fig. 7c).
Chemical release of the O-glycans fromMUC1-IgG2a-STn followed
by LC-ESIMS analysis showed that 83% of the released oligosaccharides
were Neu5Ac2–6GalNAc (STn) O-glycans along with some mono-
sialylated T (Neu5Ac2–3Gal1–3GalNAc, ST 4%) and di-sialylated T
(Neu5Ac2–3Gal1–3(Neu5Ac2–6)GalNAc, di-ST 12%) (Table 2).
Thus, hST6GalNAc-I was able to compete very effectively with the core
1 enzyme to produce STn.
Stable Expression of hST6GalNAc-I in CHOCells Reduces the O-Gly-
cosylation Site Occupancy in a Secreted MUC1 Glycoprotein—We also
investigated the effect of hST6GalNAc-I on the number of O-glycans
added to the secreted MUC1 glycoprotein. There are five potential
O-glycosylation sites in each tandem repeat of MUC1. In the parental
CHO-MUC1 cells, approximately half of the tandem repeats are fully
glycosylated and the rest carry either three or four O-glycans, giving an
average occupancy of 4.3 sites per tandem repeat (36). The presence of
hST6GalNAc-I significantly reduced this number to an average occu-
pancy of 3.8, with only 25% of the tandem repeats being fully glycosy-
lated, with the repeats having four O-glycans being the most common
(39%) (Fig. 8 and Table 2). A significant number of repeats (12%) had
only two sites occupied byO-glycans, which was in contrast to wt CHO
MUC1where peptides with only two GalNAcs were not detected. Thus
the expression of hST6GalNAc-I had two major effects on the glycosy-
lation of MUC1 in CHO cells. Firstly, the majority of the O-glycans
addedwere STn instead of di- ormono-sialylated T, and secondly, there
was a reduced occupancy of the five possibleO-glycosylation sites in the
tandem repeat of MUC1.
DISCUSSION
The simple disaccharide Neu5Ac2,6GalNAc linked to serine or
threonine, the STn epitope, has a highly restricted expression on normal
tissues (28–30) but is found on several carcinomas, including breast (19,
28, 31). The STn epitope is synthesized through the pathway of mucin
type O-glycosylation, where sugars are added individually and sequen-
tially, each addition being catalyzed by a glycosyltransferase, or in some
cases by a family of enzymes. There are for example multiple enzymes
(polypeptide GalNAc transferases), which catalyze the addition of the
first sugar N-acetylgalactosamine to serines and threonines (42), and
these are localized throughout theGolgi pathway (41). Thusmucin-type
O-glycosylation can be initiated in all compartments of the Golgi. Gly-
coproteins carrying GalNAc are substrates for any enzyme that adds a
second sugar in the synthetic pathway. For the synthesis of the STn
disaccharide in breast cancer cells, our results indicate that the enzyme
responsible is hST6GalNAc-I. Thus we have demonstrated a complete
correlation between the expression of hST6GalNAc-I in breast carcino-
mas and the expression of STn and shown expression of STn in breast
cancer cells transfected with the enzyme. This is in contrast to the total
lack of correlation between hST6GalNAc-II and STn expression and
the lack of expression of STn in cells transfected with this enzyme.
Because there is a lack of detectable hST6GalNAc-ImRNA in the nor-
mal human mammary gland (see Fig. 2), we conclude that in breast
cancer the presence of STn in 30% of these tumors is the result of the
switching on of the hST6GalNAc-I gene.
Our findings are in contrast to the data relating to the appearance of
STn in colon cancers, where no correlation was found between the
activity of 2,6-sialyltransferase(s) adding sialic acid to GalNAc and
STn expression in cancer tissues (32). The explanation for the apparent
de novo expression of STn in colon cancer relates to a modification of
the sialic acid in the cells of normal colonic tissues. The sialic acid added
to GalNAc in the normal colonic epithelium is O-acetylated and not
recognized by the antibodies used to detect STn, whereas in colon can-
cer cells,O-acetylation is reduced and the STn epitope is unmasked and
recognized by the antibodies (38, 43). This reduction in sialic acid
O-acetylation appears to be an early event in the process of malignant
transformation in human colorectal cancer (44). However, in hepato-
cellular carcinoma, the underlying mechanism for the expression of
STn is not due to a loss of O-acetylation of sialic acid (45) and could
relate to changes in sialyltransferase expression as we have observed in
breast cancer.
Although levels of expression of glycosyltransferases can give an indi-
cation of the potential pathways of glycosylation, the final composition
of theO-glycan is also crucially dependent on the position of the enzyme
in the Golgi stacks. This is particularly relevant to those steps in glycan
synthesis where enzymes producing different products are competing
for the same substrate. The enzyme responsible for initiation of chain
extension in breast cancer is the core 1 enzyme that adds galactose to
GalNAc and thus potentially can compete with hST6GalNAc-I for the
GalNAc substrate. The core 1-synthesizing enzyme is very widely dis-
tributed, but its position in the Golgi pathway has not yet been deter-
mined. Here we show that the transfected hST6GalNAc-I enzyme, like
the polypeptide GalNAc transferases, appears to be distributed
throughout the Golgi stacks (Fig. 5), which would allow access to the
GalNAc substrate even in the cis Golgi. This positioning would explain
our observation that, even when a functional core 1 (and even core 2)
enzyme is expressed, expression of hST6GalNAc-1 can override this
pathway to a large extent. Indeed, when ST6GalNAc-I was expressed in
CHO cells, which express core 1 but no core 2 enzymes, 83% of the
O-glycans added toMUC1were STn.Other sialyltransferases have been
localized toward the trans compartment of theGolgi, but these enzymes
are adding sialic acid to glycans that have been extended in passing
through theGolgi (12). Confirmation of theGolgi localization of endog-
enous ST6GalNAc-I awaits the development of a specific monoclonal
antibody.
The expression of functional ST6GalNAc-I not only altered the
O-glycan structures but also reduced the site occupancy of the potential
five O-glycosylation sites in the MUC1 tandem repeat. It appears that
the addition of sialic acids to the core GalNAcs inhibits, to some degree,
the subsequent action of polypeptide-GalNAc transferases with the
result that fewer GalNAcs are added to the protein. This may be due to
sialic acid interfering with the binding of the lectin domains of polypep-
tide GalNAcT, which is required for their action (46), and is possible
because ST6GalNAc-I, like the GalNAc transferases, is found through-
out the Golgi. Reducing the number of sites glycosylated leads to expo-
sure of antigenic epitopes in the protein, which, combined with the
multiple novel STn epitopes, will radically change the antigenicity of
the MUC1 glycoform expressed in ST6GalNAc-I-expressing breast
cancers.
STn expression is associated with poor prognosis in breast (20, 47)
and other carcinomas (48, 49).Moreover, in node-positive breast cancer
patients, STn expression is correlatedwith a lack of response to adjuvant
chemotherapy (19). The expression of this carbohydrate antigen there-
fore appears to be identifying a particular group of patients that may
benefit from some other form of treatment. An immunotherapeutic
approach could be one such treatment, and we have developed a CHO
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cell line that secretes large quantities of MUC1-expressing STn (Fig. 7
andTable 2). Indeed, the first experiments using this product in amouse
model where MUC1 is expressed as a self-antigen demonstrate that
specific antibodies can be induced, which recognize the STn glycoform
of MUC1 but not other glycoforms.7 The availability of MUC1-STn as
produced by the modified CHO cells will now allow the evaluation of
this glycoprotein as an immunogen for effects on STn-expressing
tumors.
Acknowledgment—We thank Professor Philippe Delannoy for the kind gift of
ST6GalNAc-II cDNA.
REFERENCES
1. Lowe, J. B., and Marth, J. D. (2003) Annu. Rev. Biochem. 72, 643–691
2. Wells, L.,Whelan, S. A., andHart, G.W. (2003)Biochem. Biophys. Res. Commun. 302,
435–441
3. Hakomori, S. (2004) Arch. Biochem. Biophys. 426, 173–181
4. Hakomori, S. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 10231–10233
5. Hull, S. R., Bright, A., Carraway, K. L., Abe, M., Hayes, D. F., and Kufe, D. W. (1989)
Cancer Commun. 1, 261–267
6. Lloyd, K. O., Burchell, J., Kudryashov, V., Yin, B. W., and Taylor-Papadimitriou, J.
(1996) J. Biol. Chem. 271, 33325–33334
7. Muller, S., and Hanisch, F. G. (2002) J. Biol. Chem. 277, 26103–26112
8. Hanisch, F. G., Uhlenbruck, G., Peter-Katalinic, J., Egge, H., Dabrowski, J., and Dab-
rowski, U. (1989) J. Biol. Chem. 264, 872–883
9. Brockhausen, I., Yang, J. M., Burchell, J., Whitehouse, C., and Taylor-Papadimitriou,
J. (1995) Eur. J. Biochem. 233, 607–617
10. Burchell, J., Poulsom, R., Hanby, A., Whitehouse, C., Cooper, L., Clausen, H., Miles,
D., and Taylor-Papadimitriou, J. (1999) Glycobiology 9, 1307–1311
11. Burchell, J. M., Mungul, A., and Taylor-Papadimitriou, J. (2001) J. Mammary Gland.
Biol. Neoplasia 6, 355–364
12. Whitehouse, C., Burchell, J., Gschmeissner, S., Brockhausen, I., Lloyd, K. O., and
Taylor-Papadimitriou, J. (1997) J. Cell Biol. 137, 1229–1241
13. Dalziel, M.,Whitehouse, C., McFarlane, I., Brockhausen, I., Gschmeissner, S., Schwi-
entek, T., Clausen, H., Burchell, J. M., and Taylor-Papadimitriou, J. (2001) J. Biol.
Chem. 276, 11007–11015
14. Johnson, T. K., Cole, W., Quaife, R. A., Lear, J. L., Ceriani, R. L., Jones, R. B., and
Cagnoni, P. J. (2002) Cancer 94, 1240–1248
15. Burchell, J., Graham, R., and Taylor-Papadimitriou, J. (1993) Cancer Surv. 18,
135–148
16. Taylor-Papadimitriou, J., Stewart, L., Burchell, J., and Beverley, P. (1993) Ann. N. Y.
Acad. Sci. 690, 69–79
17. Mungul, A., Cooper, L., Brockhausen, I., Ryder, K., Mandel, U., Clausen, H., Rughetti,
A., Miles, D. W., Taylor-Papadimitriou, J., and Burchell, J. M. (2004) Int. J. Oncol. 25,
937–943
18. Imai, J., Ghazizadeh, M., Naito, Z., and Asano, G. (2001) Anticancer Res. 21,
1327–1334
19. Miles, D. W., Happerfield, L. C., Smith, P., Gillibrand, R., Bobrow, L. G., Gregory,
W. M., and Rubens, R. D. (1994) Br. J. Cancer 70, 1272–1275
20. Leivonen, M., Nordling, S., Lundin, J., von Boguslawski, K., and Haglund, C. (2001)
Oncology. 61, 299–305
21. Longenecker, B. M., Reddish, M., Koganty, R., and MacLean, G. D. (1993) Ann. N. Y.
Acad. Sci. 690, 276–291
22. MacLean, G. D., Reddish, M., Koganty, R. R., Wong, T., Gandhi, S., Smolenski, M.,
Samuel, J., Nabholtz, J. M., and Longenecker, B. M. (1993) Cancer Immunol. Immu-
nother. 36, 215–222
23. Miles, D. W., Towlson, K. E., Graham, R., Reddish, M., Longenecker, B. M., Taylor-
Papadimitriou, J., and Rubens, R. D. (1996) Br. J. Cancer 74, 1292–1296
24. Miles, D., and Papazisis, K. (2003) Clin. Breast Cancer 3, Suppl. 4, S134–S138
25. Ikehara, Y., Kojima, N., Kurosawa, N., Kudo, T., Kono, M., Nishihara, S., Issiki, S.,
Morozumi, K., Itzkowitz, S., Tsuda, T., Nishimura, S. I., Tsuji, S., and Narimatsu, H.
(1999) Glycobiology 9, 1213–1224
26. Marcos, N. T., Pinho, S., Grandela, C., Cruz, A., Samyn-Petit, B., Harduin-Lepers, A.,
Almeida, R., Silva, F., Morais, V., Costa, J., Kihlberg, J., Clausen, H., and Reis, C. A.
(2004) Cancer Res. 64, 7050–7057
27. Samyn-Petit, B., Krzewinski-Recchi, M. A., Steelant, W. F., Delannoy, P., and Har-
duin-Lepers, A. (2000) Biochim. Biophys. Acta 1474, 201–211
28. Thor, A., Ohuchi, N., Szpak, C. A., Johnston,W.W., and Schlom, J. (1986)Cancer Res.
46, 3118–3124
29. Kjeldsen, T., Clausen,H., Hirohashi, S., Ogawa, T., Iijima,H., andHakomori, S. (1988)
Cancer Res. 48, 2214–2220
30. Cao, Y., Stosiek, P., Springer, G. F., and Karsten, U. (1996) Histochem. Cell Biol. 106,
197–207
31. Itzkowitz, S. H., Yuan,M., Montgomery, C. K., Kjeldsen, T., Takahashi, H. K., Bigbee,
W. L., and Kim, Y. S. (1989) Cancer Res. 49, 197–204
32. Vazquez-Martin, C., Cuevas, E., Gil-Martin, E., and Fernandez-Briera, A. (2004)On-
cology 67, 159–165
33. Peat, N., Gendler, S. J., Lalani, N., Duhig, T., and Taylor-Papadimitriou, J. (1992)
Cancer Res. 52, 1954–1960
34. Vitiello, A.,Marchesini, D., Furze, J., Sherman, L. A., andChesnut, R.W. (1991) J. Exp.
Med. 173, 1007–1015
35. Bartek, J., Bartkova, J., Kyprianou, N., Lalani, E. N., Staskova, Z., Shearer, M., Chang,
S., and Taylor-Papadimitriou, J. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 3520–3524
36. Backstrom, M., Link, T., Olson, F. J., Karlsson, H., Graham, R., Picco, G., Burchell, J.,
Taylor-Papadimitriou, J., Noll, T., and Hansson, G. C. (2003) Biochem. J. 376,
677–686
37. Link, T., Backstrom, M., Graham, R., Essers, R., Zorner, K., Gatgens, J., Burchell, J.,
Taylor-Papadimitriou, J., Hansson,G. C., andNoll, T. (2004) J. Biotechnol. 110, 51–62
38. Ogata, S., Koganty, R., Reddish, M., Longenecker, B. M., Chen, A., Perez, C., and
Itzkowitz, S. H. (1998) Glycoconj. J. 15, 29–35
39. Kono,M., Tsuda, T., Ogata, S., Takashima, S., Liu, H., Hamamoto, T., Itzkowitz, S. H.,
Nishimura, S., and Tsuji, S. (2000) Biochem. Biophys. Res. Commun. 272, 94–97
40. Brockhausen, I., Yang, J., Lehotay, M., Ogata, S., and Itzkowitz, S. (2001) Biol. Chem.
382, 219–232
41. Rottger, S.,White, J.,Wandall, H.H.,Olivo, J. C., Stark, A., Bennett, E. P.,Whitehouse,
C., Berger, E. G., Clausen, H., and Nilsson, T. (1998) J. Cell Sci. 111, 45–60
42. Clausen, H., and Bennett, E. P. (1996) Glycobiology 6, 635–646
43. Jass, J. R., Allison, L. J., and Edgar, S. G. (1995) J. Pathol. 176, 143–149
44. Corfield, A. P.,Myerscough, N.,Warren, B. F., Durdey, P., Paraskeva, C., and Schauer,
R. (1999) Glycoconj. J. 16, 307–317
45. Cao, Y., Karsten, U., Otto, G., and Bannasch, P. (1999) Virchows Arch. 434, 503–509
46. Hassan, H., Reis, C. A., Bennett, E. P., Mirgorodskaya, E., Roepstorff, P., Holling-
sworth, M. A., Burchell, J., Taylor-Papadimitriou, J., and Clausen, H. (2000) J. Biol.
Chem. 275, 38197–38205
47. Kinney, A. Y., Sahin, A., Vernon, S.W., Frankowski, R. F., Annegers, J. F., Hortobagyi,
G. N., Buzdar, A. U., Frye, D. K., and Dhingra, K. (1997) Cancer 80, 2240–2249
48. Itzkowitz, S. H., Bloom, E. J., Kokal, W. A., Modin, G., Hakomori, S., and Kim, Y. S.
(1990) Cancer 66, 1960–1966
49. Miles, D. W., Linehan, J., Smith, P., and Filipe, I. (1995) Br. J. Cancer. 71, 1074–1076
50. Olson, F. J., Ba¨ckstro¨m, M., Karlsson, H., Burchell, J., and Hansson, G. C. (2005)
Glycobiology 15, 177–1917 R. Sewell, unpublished observations.
ST6GalNAc-I Expression in Breast Cancer
3594 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 281•NUMBER 6•FEBRUARY 10, 2006
 at R
sch Cntr Julich Res library on August 6, 2007 
w
w
w
.jbc.org
D
ow
nloaded from
 
